SKAN Group Announces Strong Financial Performance in 2023 with Increased Sales and Margins

SKAN Group AG has reported a significant growth in sales and margins for the 2023 financial year. The company, a global leader in isolator systems for the (bio-)pharmaceutical industry, achieved a 15.5% increase in net sales, reaching CHF 320 million. This growth was evident in both of its business segments, underlining SKAN's flourishing performance across the board.

Moreover, the group's EBITDA rose by 24.9% to CHF 50.1 million, achieving an EBITDA margin of 15.7% and surpassing the communicated margin targets. This accomplishment highlights SKAN's ability to not only grow its sales but also improve profitability efficiently. The company attributes its success to strong market demand for aseptic production processes, particularly in the field of injectable drugs and biotech active ingredients.

A stable order intake of CHF 295.1 million and a substantial order backlog offer the confidence for continued growth, letting SKAN plan securely for the future. The proposed dividend of CHF 0.35 per share further illustrates the company's robust financial standing and commitment to rewarding its shareholders.

Strategically, SKAN is making progress, especially in the Equipment & Solutions business, with initiatives focused on integrated process systems and higher standardization. The noteworthy development in the Services & Consumables segment has also significantly contributed to the company's profitability.

Looking forward, SKAN Group is optimistic about 2024, supported by a full project pipeline and a strong order backlog. Continued market growth and strategic implementations are expected to further drive the company's success.